🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC

Recruitingn/aAges 18 Years - 75 YearsAllSun Yat-Sen Memorial Hospital of Sun Yat-Sen Univ…
NCT07658833 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The safety, clinical efficacy and prognostic factors of transcatheter arterial chemoembolization (TACE) and/or hepatic artery infusion chemotherapy (HAIC) combined with targeted immunotherapy for primary hepatocellular carcinoma (HCC) require further in-depth study. This research aims to evaluate the safety, clinical efficacy and prognostic factors of TACE and/or HAIC combined with targeted immunotherapy for hepatocellular carcinoma. We are going to compare and analyze local tumor response, survival outcomes, prognostic factors and adverse events. Tumor response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) version. Adverse events were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. This study intends to include the targeted and immunotherapy applied, mainly including: lenvatinib, sorafenib, apatini

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * aged 18-80 years * Eastern Cooperative Oncology Group (ECOG) performance status score \< 2 * maximum tumor diameter ≥ 7 cm * IVC/RA TT diagnosed by contrast-enhanced CT / MRI before study treatment * unresectable HCC (uHCC) confirmed by a specialized multidisciplinary team * liver function of Child-Pugh class A or B Exclusion Criteria: * with other malignancies * prior anti-tumor therapy * history of drug allergy * autoimmune diseases * digestive hemorrhage of any grade * insufficient renal, bone marrow, or coagulation function
💊

What it tests

  • TACE (transarterial chemoembolization) combined with targeted/immunotherapy
📍

Where

1 site
Jiayan Ni
Guangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy